JCR Pharmaceuticals Announces Licensing Agreement With Menagen To Commercialize Agalsidase Beta BS I.V. Infusion

Reuters
2025.10.01 17:37
Oct 1 (Reuters) - JCR Pharmaceuticals Co Ltd (4552.T) : * JCR PHARMACEUTICALS ANNOUNCES LICENSING AGREEMENT WITH MENAGEN TO COMMERCIALIZE AGALSIDASE BETA BS I.V. INFUSION (JCR) ACROSS NINE MENAT MARKETS * JCR PHARMACEUTICALS CO LTD: DOES NOT EXPECT A MATERIAL IMPACT ON FY2025 CONSOLIDATED RESULTS FROM MENAGEN DEAL Source text: Further company coverage: (4552.T) (((( Reuters.Briefs@thomsonreuters.com ;));))
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.